Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis.
about
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective reviewA case-control study of rheumatoid arthritis identifies an associated single nucleotide polymorphism in the NCF4 gene, supporting a role for the NADPH-oxidase complex in autoimmunity.The relationship of antibodies to modified citrullinated vimentin and markers of bone and cartilage destruction in rheumatoid arthritis.Assessment of peripheral neuropathy in patients with rheumatoid arthritis who complain of neurologic symptoms.Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients.Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritisClinical features of rheumatoid arthritis-associated interstitial lung disease.Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study.Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors.The influence of polygenic risk scores on heritability of anti-CCP level in RA.The phenotype and genotype of rheumatoid arthritis in the Democratic Republic of Congo.The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis.Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis.Biomarkers of rheumatoid arthritis: recent progress.Overview of vasculitis and vasculopathy in rheumatoid arthritis--something to think about.Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.Citrullination of autoantigens implicates NETosis in the induction of autoimmunity.Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects.High titer of anti-citrullinated peptide antibody is a risk factor for severe carotid atherosclerotic plaque in patients with rheumatoid arthritis: the TOMORROW study.The Complex Role of the Lung in the Pathogenesis and Clinical Outcomes of Rheumatoid Arthritis.The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting.Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life.Reduced incidence of extra-articular manifestations of RA through effective disease control: Karnataka Rheumatoid Arthritis Comorbidity (KRAC) study.Rheumatoid arthritis during pregnancy and postnatal catch-up growth in the offspring.Personalized medicine in rheumatology: the paradigm of serum autoantibodies.Incidence rate of falls and its risk factors in patients with rheumatoid arthritis compared to controls: Four years of the TOMORROW study.Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease.Effect of tobacco smoking on tissue protein citrullination and disease progression in patients with rheumatoid arthritis.Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies.An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management.Ethnic differences in the prognostic utility of rheumatoid factor isotypes and anticyclic citrullinated peptides in rheumatoid arthritis patients: a cross-sectional study.Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis.Biomarkers in connective tissue diseases.Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations.The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients.The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients.Hearing impairment in patients with rheumatoid arthritis: association with anti-citrullinated protein antibodies.The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis.Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis.
P2860
Q26775753-865F6794-1D9E-4205-BDED-105486DC162EQ33300467-4211C149-9584-4D8A-93CE-283B1D88AA63Q33563097-EEC54C38-CE09-47DD-81E8-6845E5DAD569Q33633565-7E5A4DC6-FD78-4C51-B381-E027836035F7Q33637585-73A8AC67-D5E2-474E-BE98-33B25054ADB5Q35067205-CEA1D033-524C-46C7-A014-83DCED7001C4Q36128529-A6FE3579-BBB1-4658-9472-1D329C72AA7FQ36213507-A6B7E487-B879-4586-80AE-695A02A4821CQ36951050-5A84F198-A144-4BEB-B5DB-64CA8C340ACAQ37627646-85BB40BC-32AB-4029-A7ED-D748F0129F43Q37691038-A8529CDE-5E77-4306-90BF-75F2C6807FD5Q37710782-518D8A60-7127-4AC3-83F3-FAFA9DC0AE0AQ37720317-116CCCDA-1F8F-487D-A0FC-89F5E6C38498Q38089869-4E39FFC1-CF2D-494A-AF14-91D94014DAFBQ38104641-2639BAD2-22A3-45A0-8F22-FC84F3250A85Q38125245-36C590B6-F982-4158-BB52-C88BD8BE4EF6Q38167579-28DEB140-AB43-4A0E-8089-4FF210EA09FEQ38663608-72A46E54-8D82-47D0-A695-5C89605E8C85Q38719851-4D7B2123-BB2F-4DBD-B356-310DD2B71D5FQ38994767-C51C7058-E60A-44DF-98AD-A7FD6294418DQ39029106-A1989EE5-8A68-4E1D-B2C3-E4480C30BCDEQ39091666-28D29624-8FDB-4CFE-8A01-F1DCD2A182D2Q39108628-274C409D-929A-4A07-97D0-316B2C4DA009Q39243131-60211ABC-EB64-49A3-AB57-4F43A64969B9Q39432157-2E7AA5A3-1DDB-495D-B803-32DCAFD3B77CQ39797546-8B1BE2C2-5782-4C42-A2BB-A4384C723E6FQ40338691-1A95A6A1-0E77-4E7E-9EF4-FC1E67C6E970Q42029622-6060799F-D919-43A5-86BB-A91ECD61E38EQ42659601-5A027EEB-7A3C-4071-B1ED-9B4B7459FAEBQ42699610-54919BDB-F5C8-4E5B-A96D-1D7B38FA348CQ44646567-19E27703-15EF-4E11-845B-7B666078FB7AQ46402982-AD0DC1F7-6E36-41F8-BA8A-6A8DE5BD7281Q47314399-CE8221F3-B560-4569-92AB-7F660DA9D018Q48008568-A8FE4A4E-6AE9-4880-872C-07234664D6B1Q49787347-3339AB2B-FE91-45A1-A77A-1246BF1B4A9EQ50122396-395DBEF2-2C83-49E9-8B9E-F6B325133E3AQ50316556-C4B513EE-4146-45A9-9C30-B33402CC58ECQ51068510-BE495294-D82C-47CD-B530-8308DF98A4EDQ51273023-9EC06159-2308-4D90-892D-93156467E9B7Q51824341-167257FF-93DB-407A-81F6-7E34A1EF2808
P2860
Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Rheumatoid factor and antibodi ...... tions in rheumatoid arthritis.
@ast
Rheumatoid factor and antibodi ...... tions in rheumatoid arthritis.
@en
type
label
Rheumatoid factor and antibodi ...... tions in rheumatoid arthritis.
@ast
Rheumatoid factor and antibodi ...... tions in rheumatoid arthritis.
@en
prefLabel
Rheumatoid factor and antibodi ...... tions in rheumatoid arthritis.
@ast
Rheumatoid factor and antibodi ...... tions in rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Rheumatoid factor and antibodi ...... tions in rheumatoid arthritis.
@en
P2093
C Turesson
E L Matteson
G Sturfelt
J Rönnelid
L Mathsson
L T H Jacobsson
P2860
P356
10.1136/ARD.2006.054445
P407
P577
2006-08-10T00:00:00Z